3.90
-0.25(-6.02%)
Currency In USD
| Previous Close | 4.15 |
| Open | 4.09 |
| Day High | 4.18 |
| Day Low | 3.78 |
| 52-Week High | 91.25 |
| 52-Week Low | 3.63 |
| Volume | 126,034 |
| Average Volume | 299,863 |
| Market Cap | 4.72M |
| PE | -0.08 |
| EPS | -49.75 |
| Moving Average 50 Days | 9.36 |
| Moving Average 200 Days | 15.64 |
| Change | -0.25 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.22 as of December 24, 2025 at a share price of $3.9. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $1.99 as of December 24, 2025 at a share price of $3.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
GlobeNewswire Inc.
Dec 17, 2025 1:31 PM GMT
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
GlobeNewswire Inc.
Dec 10, 2025 1:30 PM GMT
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today annou
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
GlobeNewswire Inc.
Dec 09, 2025 1:07 PM GMT
Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial HOUSTON, Dec. 09, 2025 (GLOBE NEWSW